Acadia Pharmaceuticals Incorporated
Short Squeeze Ranking™
Daily Short Sale Volume
Daily Naked Short Selling List
Short Interest (Shares Short)
Short Interest Ratio (Days To Cover)
Short Percent of Float
Short % Increase / Decrease
Short Interest (Shares Short) - Prior
Type Value Conf.
resist. 36.06 4
supp 35.24 6
supp 33.95 5
supp 30.62 2
supp 29.74 2
supp 28.68 2
supp 27.63 2
supp 26.87 4
supp 24.61 4
supp 21.76 2
supp 20.89 3
supp 19.23 2
supp 17.32 4
so stockta only lists S&R for the 3 month chart. But looking at the yahoo 1 yr charts, looks like next major
Resistance is approx $39 and change.
Great find for the believers. I took a look it this am. In retrospect even after the positive data release I would not have bought it. Its not the type of biotech that interests me. Very small sector of patients, maybe ? 10K/yr. And before the data release I wouldn't have bought it either, difficult cancers, AML as I recall. Thing is, it is a good match for JAZZ, an easy buy, but Total Cash 980 Mill -( they could never buy ACAD). A low hanging fruit. Also the drug is not FDA approved yet. But still those who are in, congrats.
It is what it is, the "firm" is just the money changer, so they shake the tree every now and them to drum up some business. I didn't see many complaints when it ran up like 10 days in a row. Better get use to it. I mean they get FDA approved and the stock goes down, Ugh! Now launch and 13 cents up, not a great response-the IBB having a nice day though. Basically we are way Over Bought and bumping up against some moderate Resistance. We could see some pull back. Again if you use Stops you will lose your shares.
Great news...( --You now have Nuplazid )....interesting the company announced launch would be in June...I figured about June 15. But not complaining just think its odd.
Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes including hyperglycemia/diabetes mellitus, dyslipidemia, and weight gain. Clinical monitoring is recommended.
Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia, neutropenia, and agranulocytosis have been reported with antipsychotic use. Perform complete blood count (CBC) in patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia or neutropenia. Consider discontinuing REXULTI if a clinically significant decline in WBC count occurs in the absence of other causative factors.
Orthostatic Hypotension and Syncope: REXULTI should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions which would predispose them to hypotension.
Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold.
Body Temperature Dysregulation: Appropriate care is advised for patients who may exercise strenuously, be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or be subject to dehydration.
Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. REXULTI should be used with caution in patients at risk for aspiration pneumonia.
Potential for Cognitive and Motor Impairment: REXULTI may have the potential to impair judgment, thinking, or motor skills. Patients should not drive or operate hazardous machinery until they are certain REXULTI does not affect them adversely.
Alcohol: Advise patients to avoid alcohol while taking REXULTI.
Concomitant Medication: Administer half the dose of REXULTI with strong CYP2D6 or CYP3A4 inhibitors. Administer a quarter of the dose with strong/moderate CYP2D6 inhibitors or known CYP2D6 poor metabolizers taken with strong/moderate CYP3A4 inhibitors. Double the dose with strong CYP3A4 inducers over 1 to 2 weeks.
In clinical trials examining the adjunctive use of REXULTI in the treatment of MDD, dosage was not adjusted for strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). CYP considerations were already factored into general dosing recommendations for MDD. Thus, REXULTI may be administered without dosage adjustment in these patients.
Most commonly observed adverse reactions: Adult patients with major depressive disorder (adjunctive treatment to antidepressant therapy; ≥5% incidence and at least twice the rate of placebo for REXULTI vs. placebo, respectively): akathisia (9% vs. 2%) and weight increase (7% vs. 2%). Adult patients with schizophrenia (≥4% incidence and at least twice the rate of placebo for REXULTI vs. placebo, respectively): weight increased (4% vs. 2%).
Dystonia: Dystonia may occur in susceptible individuals during the first days of treatment and at low doses.
Pregnancy: Non-Teratogenic Effects – Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. REXULTI should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known if REXULTI is excreted in human breast milk. Discontinue the drug or nursing, taking into account the importance of the drug to the mother.
REXULTI is indicated for:
Use as an adjunctive therapy to antidepressants in adults with major depressive disorder
Treatment of schizophrenia in adults
This medication is used to treat certain mental/mood disorders (such as schizophrenia, depression). Brexpiprazole helps you to think more clearly, feel less nervous, and take part in everyday life. It may also help to decrease hallucinations (hearing/seeing things that are not there). In addition, this medication may improve your mood, sleep, appetite, and energy level. Brexpiprazole is a psychiatric medication that belongs to the class of drugs called atypical antipsychotics. It works by helping to restore the balance of certain natural substances in the brain.
IMPORTANT SAFETY INFORMATION AND INDICATIONS for REXULTI® (brexpiprazole)
IMPORTANT SAFETY INFORMATION
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo. REXULTI is not approved for the treatment of patients with dementia-related psychosis.
Suicidal Thoughts and Behaviors
Antidepressants increase the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. All patients on antidepressant therapy should be monitored and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Also, families and caregivers should be advised to closely observe these patients and communicate with the prescriber. REXULTI is not approved for use in pediatric patients with depression.
See Full Prescribing Information for complete Boxed WARNING.
Contraindication: Known hypersensitivity reaction to REXULTI or any of its components. Reactions have included: rash, facial swelling, urticaria and anaphylaxis.
Cerebrovascular Adverse Events, Including Stroke: In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly patients with dementia, there was a higher incidence of cerebrovascular adverse reactions (stroke, TIA), including fatalities, compared to placebo-treated patients.
Neuroleptic Malignant Syndrome (NMS): A potentially fatal complex sometimes referred to as NMS has been associated with the administration of antipsychotic drugs. Manage with immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring.
Tardive Dyskinesia (TD): REXULTI should be prescribed in a manner most likely to minimize the occurrence of TD. If signs and symptoms of TD appear, drug discontinuation should be considered.
Metabolic Changes: Atypical antipsychotic drugs have been ass